Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

MegaRetarded Mar. 9 at 2:27 PM

$MBIO heading back to 50 cents again

0 · Reply

JTE_Theta Mar. 5 at 4:12 PM

Disseminated on behalf of MindBio Therapeutics (CSE: $MBIO) (OTCQB: $MBQIF) AI Voice Tech Turning Human Speech Into Real Time Risk Signals 🧬 With 50M+ voice data points, their platform detects cognitive & physiological biomarkers from short voice samples ! No hardware, No wearables, No invasive testing. CommunicatedDisclaimer: http://tinyurl.com/54jmx7k9

1 · Reply

JTE_Theta Mar. 4 at 1:51 AM

🧠The Mental Health Market Is Broken. $MBIO / $MBQIF Is Building Something Different. Traditional antidepressants can take weeks to work, often come with heavy side effects, and don’t help everyone. MindBio Therapeutics Corp is developing regulated, take-home psychedelic microdosing therapies designed for scalable treatment of depression, anxiety, PTSD, and cancer related distress. Their lead program, MB22001, is currently in Phase 2 clinical development -Ttargeting structured protocols that could move psychedelic therapy beyond clinics and into accessible, real world care. Why this is interesting 🧠 • Focus on regulated take home model vs in clinic only treatments • Late stage clinical progress in a rapidly emerging sector • Integration of AI health monitoring tech for data + safety • Exposure to a multi billion dollar global mental health opportunity CommunicatedDisclaimer:http://tinyurl.com/4sahjja4

1 · Reply

BillionerOfKing Feb. 22 at 2:28 PM

$MBIO Current Stock Price: $0.99

0 · Reply

FinSUN Feb. 21 at 9:40 AM

$MBIO let this miserable pos die

0 · Reply

FinSUN Feb. 21 at 9:29 AM

$MBIO Considering Fortress history, both recent and old one, these scammers allmost certainly "work" for B Riley. What else do you expect ? Classy ! 😂😂

0 · Reply

FinSUN Feb. 21 at 9:24 AM

$MBIO typical of a paid shill 🤣🤣 zero financial arguments, 100% personal offenses. Your miserable life means nothing and you know it. Time to find a new job...

0 · Reply

QuantNut Feb. 21 at 6:09 AM

$MBIO spoken like a true loser. keep buying lube for your hands 😘

1 · Reply

FinSUN Feb. 20 at 11:34 PM

$MBIO still here trying to lure victims for your bosses' ATM ? get a life, I mean a decent one. Squeeze of a 0.86% short interest? GTFO Parasites.

0 · Reply

SMM82 Feb. 20 at 10:43 PM

$MBIO Nice bounce from ATL to the 50 day. MB-101/108/109 News would be nice, but they still need to raise to fund on. Barring any type of M&A, hard to get excited other than a technical bounce ☹️

0 · Reply

Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 8:30 AM EDT - 9 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mar 5, 2025, 4:15 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 1 year ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 2 years ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 2 years ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 2 years ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 2 years ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 2 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 3 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 3 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 3 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 3 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 3 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

MegaRetarded Mar. 9 at 2:27 PM

$MBIO heading back to 50 cents again

0 · Reply

JTE_Theta Mar. 5 at 4:12 PM

1 · Reply

JTE_Theta Mar. 4 at 1:51 AM

1 · Reply

BillionerOfKing Feb. 22 at 2:28 PM

$MBIO Current Stock Price: $0.99

0 · Reply

FinSUN Feb. 21 at 9:40 AM

$MBIO let this miserable pos die

0 · Reply

FinSUN Feb. 21 at 9:29 AM

$MBIO Considering Fortress history, both recent and old one, these scammers allmost certainly "work" for B Riley. What else do you expect ? Classy ! 😂😂

0 · Reply

FinSUN Feb. 21 at 9:24 AM

$MBIO typical of a paid shill 🤣🤣 zero financial arguments, 100% personal offenses. Your miserable life means nothing and you know it. Time to find a new job...

0 · Reply

QuantNut Feb. 21 at 6:09 AM

$MBIO spoken like a true loser. keep buying lube for your hands 😘

1 · Reply

FinSUN Feb. 20 at 11:34 PM

$MBIO still here trying to lure victims for your bosses' ATM ? get a life, I mean a decent one. Squeeze of a 0.86% short interest? GTFO Parasites.

0 · Reply

SMM82 Feb. 20 at 10:43 PM

$MBIO Nice bounce from ATL to the 50 day. MB-101/108/109 News would be nice, but they still need to raise to fund on. Barring any type of M&A, hard to get excited other than a technical bounce ☹️

0 · Reply

Vinniesb Feb. 20 at 8:51 PM

$MBIO

0 · Reply

MegaRetarded Feb. 20 at 8:40 PM

$MBIO it's been a constructive couple of weeks considering how gloomy things were looking

0 · Reply

QuantNut Feb. 18 at 9:09 PM

$MBIO smells like something finally brewing

0 · Reply

GeorgeDower518 Feb. 18 at 1:08 PM

$MBIO Biotech with platform promise but funding risk.

0 · Reply

OfficialStocktwitsUser Feb. 17 at 2:00 PM

$MBIO RSI: 36.27, MACD: -0.0605 Vol: 0.12, MA20: 0.92, MA50: 1.04 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

QuantNut Feb. 13 at 2:07 AM

$MBIO to squeeze or not to squeeze…time will tell

0 · Reply

SMM82 Feb. 12 at 1:15 AM

$MBIO Glad to see this one isn’t aging well (yet)

0 · Reply

Vinniesb Feb. 11 at 4:22 PM

$MBIO Still Bullish!

0 · Reply

QuantNut Feb. 10 at 10:25 PM

$MBIO tomorrow.

0 · Reply

Whiskey1679 Feb. 9 at 9:55 PM

See my Pinned Time Stamp Post for another 100% 🏆 WINNER 🏆!! AH Gainers: $TNMG $ALAB $UPXI $ANY $MBIO Dou

0 · Reply

SMM82 Feb. 7 at 2:20 AM

$MBIO Only down -18% this week… fresh all time lows next week.

1 · Reply

BillionerOfKing Feb. 6 at 10:05 PM

$MBIO Current Stock Price: $0.83

0 · Reply

Market Cap	6.88M
Revenue (ttm)	0.00
Net Income (ttm)	-15.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	28,500
Avg Vol	204,546
Day's Range	N/A - N/A
Shares Out	7.30M
Stochastic %K	71%
Beta	2.13
Analysts	Strong Buy
Price Target	$8.00